TOT Biopharm
Launch date
Employees
Market cap
$166m
Enterprise valuation
$164m (Public information from Sep 2024)
Share price
HKD2 1875.HK
China (HQ)
Financials
Estimates*
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 45.3m | 22.5m | 76.3m | 442m | 781m | 5.9b | 6.1b |
| % growth | - | (50 %) | 239 % | 479 % | 77 % | 652 % | 3 % |
| EBITDA | (240m) | (255m) | (219m) | (3.4m) | 24.4m | - | - |
| % EBITDA margin | (530 %) | (1136 %) | (287 %) | (1 %) | 3 % | - | - |
| Profit | (299m) | (288m) | (261m) | (49.9m) | (37.8m) | - | - |
| % profit margin | (661 %) | (1283 %) | (342 %) | (11 %) | (5 %) | - | - |
| R&D budget | 191m | 235m | 215m | 151m | 104m | - | - |
| R&D % of revenue | 422 % | 1046 % | 281 % | 34 % | 13 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$6.0m | Series A | ||
* | $102m | Series B | |
| N/A | N/A | IPO | |
| Total Funding | $108m | ||
Related Content
Recent News about TOT Biopharm
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.